文献速递胸部肿瘤

肺腺癌中MET外显子14跳跃突变的临床病理意义与预后价值

MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values.
PubMed 文献 · J Thorac Oncol · 2017-05-10

在795例接受手术的东亚NSCLC患者中,对45例五阴性肺腺癌行RT-PCR筛查,发现17例(37.8%)存在METex14跳跃突变。该突变与高龄、腺泡或实性亚型及高MET免疫组化表达相关,预后与主要驱动突变患者相似;MET免疫组化灵敏度100%、特异度70.4%。

要点

  • 五阴性肺腺癌中METex14跳跃突变检出率为37.8%(17/45)。
  • MET免疫组化检测METex14跳跃突变的灵敏度为100%、特异度为70.4%。
  • I-IIIA期METex14跳跃突变患者复发率高于ALK融合患者(HR=0.283,95%CI:0.119-0.670)。

核心结论

  • 在无其他驱动突变的东亚肺腺癌患者中METex14跳跃突变患病率较高,与高龄、腺泡或实性亚型及高MET免疫组化表达相关,预后与主要驱动突变患者相似。

研究设计与样本

  • 对795例接受手术的东亚NSCLC患者中的45例五阴性(EGFR阴性/KRAS阴性/ALK阴性/ROS1阴性/RET阴性)肺腺癌,采用逆转录聚合酶链反应筛查METex14跳跃突变。
  • 另用靶向跳跃连接处的小干扰RNA(siRNA)在METex14跳跃突变细胞中研究其对MET驱动信号通路的影响。

主要发现

  • 17例患者中位年龄73岁,腺泡亚型占52.9%,实性亚型占35.3%。
  • MET免疫组化检测METex14跳跃突变的灵敏度为100%、特异度为70.4%。
  • 多因素分析显示I-IIIA期METex14跳跃突变患者复发率高于ALK融合患者(HR=0.283,95%CI:0.119-0.670)。
  • 调整病理分期后总生存差异无统计学意义(p=0.669)。
  • siRNA降低Hs746T细胞中MET驱动信号通路,siRNA与克唑替尼联合抑制克唑替尼耐药H596细胞增殖。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Response to mesenchymal-epithelial transition (MET) inhibitors in NSCLC with mesenchymal-epithelial transition gene (MET) exon 14 skipping (METex14) has fueled molecular screening efforts and the search for optimal therapies. However, further work is needed to refine the clinicopathologic and prognostic implications of METex14 skipping. METHODS: Among 795 East Asian patients who underwent a surgical procedure for NSCLC, we screened 45 patients with quintuple-negative (EGFR-negative/KRAS-negative/anaplastic lymphoma kinase gene [ALK]-negative/ROS1-negative/ret proto-oncogene [RET]-negative) lung adenocarcinomas by using reverse-transcriptase polymerase chain reaction and found 17 patients (37.8%) with METex14 skipping. We also investigated the effect of small interfering RNA (siRNA) targeting skipping junction in cells with METex14 skipping. RESULTS: The median age of the 17 patients was 73 years. The acinar subtype was predominant (52.9%), followed by the solid subtype (35.3%). MET immunohistochemistry demonstrated 100% sensitivity and 70.4% specificity. Multivariate analyses showed that patients with METex14 skipping had a higher recurrence rate than those with ALK fusion (versus METex14 skipping) (hazard ratio = 0.283, 95% confidence interval: 0.119-0.670) in stage I to IIIA disease; however, the differences in overall survival were not significant after adjustment for pathologic stage (p = 0.669). Meanwhile, siRNA decreased MET-driven signaling pathways in Hs746T cells, and combined treatment with siRNA and crizotinib inhibited cell proliferation in crizotinib-resistant H596 cells. CONCLUSIONS: The prevalence of METex14 skipping was quite high in East Asian patients without other driver mutations in lung adenocarcinomas. METex14 skipping was associated with old age, the acinar or solid histologic subtype, and high MET immunohistochemical expression. The prognosis of patients with METex14 skipping was similar to that of patients with major driver mutations. siRNA targeting the junction of METex14 skipping could inhibit MET-driven signaling pathways in cells with METex14 skipping.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Lee GD, Lee SE, Oh DY, et al. MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values. J Thorac Oncol. 2017. PMID: 28502721. doi:10.1016/j.jtho.2017.04.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。